Shares of CME Group Inc (NASDAQ:CME) have earned a consensus recommendation of “Buy” from the sixteen ratings firms that are covering the stock, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $157.25.
Several research firms have commented on CME. BidaskClub cut shares of CME Group from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Bank of America lifted their target price on shares of CME Group from $175.00 to $185.00 and gave the stock a “buy” rating in a research note on Thursday, March 8th. ValuEngine cut shares of CME Group from a “buy” rating to a “hold” rating in a research note on Wednesday, March 7th. Zacks Investment Research cut shares of CME Group from a “buy” rating to a “hold” rating in a research note on Tuesday, March 6th. Finally, Goldman Sachs Group raised shares of CME Group from a “neutral” rating to a “buy” rating and set a $180.00 price objective for the company in a research note on Wednesday, February 7th.
In related news, insider Derek Sammann sold 2,400 shares of the company’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $161.66, for a total transaction of $387,984.00. Following the completion of the sale, the insider now directly owns 40,153 shares of the company’s stock, valued at approximately $6,491,133.98. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Ronald A. Pankau sold 200 shares of the company’s stock in a transaction on Wednesday, February 14th. The stock was sold at an average price of $159.91, for a total transaction of $31,982.00. Following the sale, the director now directly owns 3,809 shares of the company’s stock, valued at $609,097.19. The disclosure for this sale can be found here. Insiders have sold a total of 43,024 shares of company stock valued at $6,620,113 over the last three months. Corporate insiders own 0.57% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the stock. Comerica Bank boosted its position in CME Group by 0.4% during the 4th quarter. Comerica Bank now owns 84,159 shares of the financial services provider’s stock worth $13,044,000 after purchasing an additional 313 shares during the period. Daiwa Securities Group Inc. boosted its position in CME Group by 2.5% during the 4th quarter. Daiwa Securities Group Inc. now owns 14,590 shares of the financial services provider’s stock worth $2,131,000 after purchasing an additional 362 shares during the period. ARGI Investment Services LLC boosted its position in CME Group by 6.4% during the 3rd quarter. ARGI Investment Services LLC now owns 6,326 shares of the financial services provider’s stock worth $856,000 after purchasing an additional 378 shares during the period. BB&T Securities LLC boosted its position in CME Group by 8.7% during the 4th quarter. BB&T Securities LLC now owns 4,852 shares of the financial services provider’s stock worth $708,000 after purchasing an additional 388 shares during the period. Finally, Oppenheimer & Co. Inc. lifted its holdings in CME Group by 1.0% in the 4th quarter. Oppenheimer & Co. Inc. now owns 47,233 shares of the financial services provider’s stock worth $6,898,000 after buying an additional 447 shares in the last quarter. 83.13% of the stock is owned by hedge funds and other institutional investors.
CME Group (CME) traded up $0.18 during mid-day trading on Friday, reaching $165.57. 1,790,773 shares of the company’s stock traded hands, compared to its average volume of 1,673,168. The stock has a market cap of $55,465.73, a PE ratio of 13.87, a P/E/G ratio of 2.40 and a beta of 0.54. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.03 and a quick ratio of 1.03. CME Group has a 12-month low of $114.82 and a 12-month high of $171.71.
CME Group (NASDAQ:CME) last released its earnings results on Thursday, February 1st. The financial services provider reported $1.12 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.10 by $0.02. The firm had revenue of $900.00 million during the quarter, compared to analysts’ expectations of $886.85 million. CME Group had a net margin of 111.49% and a return on equity of 7.68%. CME Group’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same period in the previous year, the company earned $1.14 EPS. equities analysts anticipate that CME Group will post 6.47 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 26th. Stockholders of record on Friday, March 9th will be paid a dividend of $0.70 per share. The ex-dividend date of this dividend is Thursday, March 8th. This is a boost from CME Group’s previous quarterly dividend of $0.66. This represents a $2.80 annualized dividend and a dividend yield of 1.69%. CME Group’s payout ratio is currently 23.45%.
WARNING: This piece was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://ledgergazette.com/2018/03/16/cme-group-inc-cme-receives-157-25-consensus-target-price-from-brokerages.html.
About CME Group
CME Group Inc, through its exchanges, provides products across all asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural products and metals. The Company’s segment primarily consists of the Chicago Mercantile Exchange Inc (CME), Board of Trade of the City of Chicago, Inc (CBOT), New York Mercantile Exchange, Inc (NYMEX) and Commodity Exchange, Inc (COMEX) exchanges.
Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.